Sisram Medical Ltd has reached a significant milestone in its journey to bring DAXXIFY, a long-acting botulinum toxin type A product, to market in China. The product has successfully passed quality testing conducted by the National Institutes for Food and Drug Control (NIFDC) of the People's Republic of China. This critical step confirms that DAXXIFY meets the rigorous standards for quality, safety, and efficacy outlined by China's national drug regulatory system.
A Revolutionary Approach to Medical Aesthetics
DAXXIFY stands out as the world's first and only peptide-formulated, long-acting neuromodulator. It uses a proprietary Peptide Exchange Technology (PXT) and stabilized peptide formulation, designed to provide both a rapid onset and prolonged duration of effect. It is specifically aimed at the temporary improvement of moderate to severe glabellar lines, resulting from muscle activity in adult patients.
By becoming the first and only botulinum toxin type A product featuring such technology to be approved in mainland China, this achievement highlights Sisram's innovation in the medical aesthetics industry. Initial commercial orders have already been established with key medical aesthetic institutions, signaling positive market reception.
sbb-itb-02f5876
Comprehensive Strategy for Commercialization
Sisram Medical has laid out an extensive plan to support the commercialization of DAXXIFY, involving various teams that are focused on market expansion, clinical support, and supply chain management. The company's experienced sales and marketing team is fostering relationships with major medical aesthetics institutions, while its dedicated medical affairs team is equipping physicians with systematic training programs and clinical evidence.
The company has also partnered with top industry players, including Fosun Wanbang (Jiangsu) and Shanghai Pharmaceuticals, to ensure a reliable and fully traceable supply chain system. This collaborative approach is designed to maintain stringent quality and compliance standards, from production to clinical delivery.
Driving Growth and Innovation
Sisram views DAXXIFY as a pivotal addition to its portfolio of injectable products and a driver of significant business growth. As the first injectable product launched in mainland China under the company's umbrella, DAXXIFY sets a new benchmark in premium medical aesthetics. With its high standards of quality and effectiveness, it is poised to cater to consumers seeking exceptional aesthetic experiences.
"The successful testing signifies the final regulatory milestone before the market launch", according to the company. Sisram has expressed confidence in DAXXIFY's potential to bolster its strategic expansion into injectables, forming what it describes as a "second growth curve." By integrating injectables alongside its existing energy-based devices (EBD), diagnostics, and complementary wellness solutions, Sisram aims to strengthen its position as a leading player in the global medical aesthetics market.
About Sisram Medical Ltd
With over 25 years of expertise, Sisram Medical Ltd has established itself as a global leader in medical aesthetics. The company offers a synergistic ecosystem that spans energy-based devices, injectables, diagnostics, and complementary solutions. Operating in more than 110 countries and regions, Sisram has built a reputation for delivering innovative and award-winning products. Majority-owned by Fosun Pharma, the company has been publicly listed on the Hong Kong Stock Exchange since 2017.
As DAXXIFY moves closer to market availability, Sisram Medical reaffirms its commitment to providing cutting-edge wellness solutions to meet the evolving needs of consumers and medical professionals alike across mainland China and beyond.
